ELVN — ENLIVEN THERAPEUTICS INC

Ownership history in CAXTON CORP  ·  2 quarters on record

This page tracks every 13F SEC filing in which CAXTON CORP reported a position in ENLIVEN THERAPEUTICS INC (ELVN). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.

Peak position
2.67% (2025 Q2)
Avg. % of fund
1.92%
First filed
2025 Q2
Last filed
2025 Q3
Quarters held
2
Quarter Action Shares Change Chg % % of Fund Mkt Value Price (EOQ)
2025 Q3 UNCHANGED 13,097 — 0% 1.17% $268K $20.47
2025 Q2 INITIATED 13,097 — — 2.67% $263K $20.06
% of Fund (quarterly)    ELVN price (monthly, adj. close)

Other funds also holding ELVN

As of 2025 Q4 — sorted by position size

Commodore Capital LP 3Y 4.81% Fairmount Funds Management LLC 3Y 4.35% 5AM Venture Management, LLC 3Y 3.74% ORBIMED ADVISORS LLC 3Y 7Y 2.5% VR Adviser, LLC 3Y 2.45% Vestal Point Capital, LP 2.01% Novo Holdings A/S 3Y 7Y 1.77% Exome Asset Management LLC 1.64% Patient Square Capital LP 3Y 1.02% SPHERA FUNDS MANAGEMENT LTD. 3Y 7Y 0.68%
← Back to CAXTON CORP Holdings